Posted by Michael Wonder on 15 Feb 2023
Kinnate Biopharma receives fast track designation from the US FDA for KIN-3248, an investigational pan FGFR inhibitor
14 February 2023 - Kinnate Biopharma today announced that the US FDA has granted fast track designation for Kinnate’s investigational pan FGFR inhibitor, KIN-3248, for the treatment of patients with unresectable, locally advanced or metastatic cholangiocarcinoma harbouring fibroblast growth factor receptor 2 gene fusions or other alterations, who have received at least one prior systemic therapy.
KIN-3248 is an irreversible, small molecule pan FGFR inhibitor designed to address primary FGFR2 and FGFR3 oncogenic alterations, including those predicted to drive acquired resistance to current FGFR targeted therapies, such as gatekeeper, molecular brake, and activation loop mutations observed in cancers such as ICC and urothelial carcinoma.
